Kyverna Therapeutics

KYTX

Market cap $525M

Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS)

EMERYVILLE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced that company management will participate in the following upcoming conferences: Leerink Partners 2026 Global Healthcare Conference Format: Fireside chat and investor meetingsDate: Monday, March 9th, 2026Time: 11:20 a.m.

Kyverna Therapeutics leads CAR-T therapy for autoimmune diseases, with KYV-101 showing unprecedented efficacy in SPS and MG registrational trials. KYTX's SPS trial achieved 81% clinically meaningful improvement and all secondary endpoints, positioning the company for a BLA filing in 1H 2026. With a $279M cash runway into 2028 and strong institutional backing, KYTX is de-risked from near-term dilution and aligns with top-tier biotech investors.

Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.

EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Mayo Pujols as its Chief Technology Officer (CTO), effective February 9, 2026.

Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026  First patient enrolled in registrational Phase 3 trial in generalized myasthenia gravis (gMG) Completed follow-on offering extends cash runway into 2028, expected to fully fund SPS BLA filing, commercial launch, and Phase 3 gMG trial Kyverna Board member, Christi Shaw, appointed as Executive Chairperson, further bolstering Company's CAR T commercialization experience; Ian Clark, former Chairperson, to remain on Board EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, provided today a corporate update and outlined its strategic priorities for 2026.

EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the J.P.

KYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.